Hanall Biopharma (009420) — Cash Flow Reinvestment Rate
Hanall Biopharma (009420) has a Cash Flow Reinvestment Rate of 0.45x as of September 2025, reinvesting ₩3.27 Billion (capex ₩3.27 Billion ) from operating cash flow of ₩7.34 Billion. Check Hanall Biopharma earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Hanall Biopharma Cash Flow Reinvestment Rate (2011–2024)
Historical reinvestment intensity for Hanall Biopharma across 10 annual periods. Explore 009420 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for Hanall Biopharma (2011–2024)
Year-by-year capital reinvestment analysis for Hanall Biopharma. For live market cap and broader valuation context, see Hanall Biopharma (009420) total market value.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 2.80x | ₩26.19 Billion | ₩9.36 Billion | ₩23.07 Billion | ▲ +293.4% |
| 2023 | 0.71x | ₩21.08 Billion | ₩29.64 Billion | ₩9.20 Billion | ▲ +211.1% |
| 2022 | 0.23x | ₩5.76 Billion | ₩25.20 Billion | ₩2.83 Billion | ▼ -99.1% |
| 2021 | 25.62x | ₩21.52 Billion | ₩839.87 Million | ₩4.61 Billion | ▲ +211.9% |
| 2020 | 8.21x | ₩7.63 Billion | ₩929.29 Million | ₩2.56 Billion | ▲ +452.7% |
| 2019 | 1.49x | ₩30.45 Billion | ₩20.49 Billion | ₩2.12 Billion | ▲ +533.8% |
| 2017 | 0.23x | ₩9.88 Billion | ₩42.14 Billion | ₩1.73 Billion | ▼ -93.8% |
| 2016 | 3.76x | ₩14.84 Billion | ₩3.95 Billion | ₩4.03 Billion | ▲ +277.6% |
| 2012 | 0.99x | ₩2.18 Billion | ₩2.20 Billion | ₩2.18 Billion | ▲ +1627.8% |
| 2011 | 0.06x | ₩426.70 Million | ₩7.41 Billion | ₩426.70 Million | — |